Industry trusted technology that has supported multiple IND filings for clinical candidates and drug approvals and continues to advance kinase drug discovery.
What is KINOMEscan?
High throughput site-directed competition affinity binding assay for rapid characterization of your molecules in over 500 kinase domain-containing human wild-type and clinically relevant mutant targets.
Benefits of KINOMEscan:
- Adaptability to screen multiple modalities (small molecules, peptides, conjugate therapies) to evaluate Type I and Type II kinase catalytic domain inhibitors, covalent inhibitors, and bifunctional degraders
- Rapid Turn-Around Time and Auto-Escalation for supporting AI and machine learning research projects
- TREEspot® Data Visualization tool with customizable reports
- Custom Assay Development for your domain of interest
TREESpot Visualization
BTK Inhibitor Selectivity TREEspot Visualization depicts kinase panel hit profile for remibrutinib (on the left), the most selective BTK inhibitor, and nemtabrutinib (on the right), the least selective BTK inhibitor, as red dots on a phylogeny of kinases. Dot size indicates hit strength, so the larger the red dot, the stronger the hit.
Key Drug Targets within KINOMEscan:
- JAK/STAT
- BTK/PLCγ/PKC
- RAS/RAF/MAPK/MEK (ERK, JNK, p38)
- PI3K/AKT/mTOR
- Wnt/β-catenin
